호르몬 대체요법 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Hormone Replacement Therapy was estimated to be worth US$ 30644 million in 2024 and is forecast to a readjusted size of US$ 35444 million by 2031 with a CAGR of 2.1% during the forecast period 2025-2031.

Hormone Replacement Therapy (HRT) is a medical intervention that supplements declining or imbalanced hormone levels in the human body to improve endocrine function, alleviate associated symptoms, and prevent chronic diseases. HRT is widely used for estrogen and progesterone supplementation in menopausal women, as well as in clinical cases of male testosterone deficiency, thyroid hormone insufficiency, and more. With advances in precision medicine and personalized healthcare, HRT products have evolved from traditional oral formulations to transdermal patches, gels, injections, and implants, supported by genetic testing, hormone level monitoring, and AI-assisted diagnostics for safer, long-term management. HRT plays a crucial role in anti-aging, quality-of-life improvement, and endocrine disease management, positioning itself as a significant growth driver in the global healthcare market.

The HRT market is rapidly expanding, driven by global population aging, rising quality-of-life demands, and the adoption of precision medicine. Public health initiatives by governments and international organizations emphasize endocrine health and chronic disease prevention, positioning HRT as an essential component of premium healthcare services. Brokerage reports indicate that pharmaceutical innovators and medical institutions are advancing personalized prescriptions and long-acting formulations to improve patient adherence and expand market potential. AI- and data-driven endocrine solutions are enabling measurable efficacy and risk management, accelerating global HRT adoption.

The industry faces regulatory scrutiny and consumer skepticism regarding long-term hormone use, which can slow adoption. High entry barriers involving clinical validation, regulatory approvals, and integrated personalized care systems raise R&D and commercialization costs. Global trade policies, raw material price fluctuations, and complex drug approval processes introduce uncertainty for multinational strategies. Analyst reports highlight that future competition will favor innovation, clinical evidence, and multi-channel service ecosystems, creating pressure for smaller players.

Demand is shifting from treatment-focused applications to preventive and functional health management. High-income populations increasingly prioritize anti-aging, emotional well-being, bone health, and sexual wellness, driving innovation in delivery formats, wearable monitoring devices, and digital health platforms. Healthcare providers and clinic networks are expanding personalized management programs, with commercial insurance accelerating coverage of HRT services. Mature markets in North America and Europe emphasize long-term adherence, while Asia-Pacific markets are emerging as growth leaders due to urbanization and evolving health awareness.

Key raw materials for HRT include estrogen, progesterone, testosterone, and thyroxine APIs, alongside polymer carriers, transdermal delivery materials, and smart monitoring components. The global API supply chain is highly concentrated, with pricing influenced by environmental regulations, compliance standards, and logistics systems. Leading firms are investing in biotech synthesis and recombinant protein technologies to optimize raw material sourcing, reduce costs, and strengthen innovation pipelines. Stricter government oversight on sustainable pharmaceutical manufacturing is steering the market toward high-value, eco-friendly solutions.

This report aims to provide a comprehensive presentation of the global market for Hormone Replacement Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Hormone Replacement Therapy by region & country, by Type, and by Application.

The Hormone Replacement Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Replacement Therapy.

Market Segmentation

By Company

• Eli Lilly
• Pfizer
• AbbVie
• Novo Nordisk
• Merck KGaA
• Viatris
• Bayer
• Teva
• Sandoz
• Abbott
• Roche
• Endo International
• Ipsen
• ANI Pharmaceuticals
• TherapeuticsMD
• Changchun Jinsai
• Takeda Pharmaceutical
• Ascendis Pharma
• Halozyme Therapeutics
• Livzon
• Hunrun Zizhu Pharma
• Hikma Pharmaceuticals

Segment by Type

• Estrogen Hormone
• Growth Hormone
• Thyroid Hormone
• Testosterone Hormone

Segment by Application

• Menopause
• Hypothyroidism
• Growth Hormone Deficiency
• Male Hypogonadism
• Other Diseases

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Hormone Replacement Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Hormone Replacement Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Hormone Replacement Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Hormone Replacement Therapy Product Introduction
• 1.2 Global Hormone Replacement Therapy Market Size Forecast (2020-2031)
• 1.3 Hormone Replacement Therapy Market Trends & Drivers
  • 1.3.1 Hormone Replacement Therapy Industry Trends
  • 1.3.2 Hormone Replacement Therapy Market Drivers & Opportunity
  • 1.3.3 Hormone Replacement Therapy Market Challenges
  • 1.3.4 Hormone Replacement Therapy Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Hormone Replacement Therapy Players Revenue Ranking (2024)
• 2.2 Global Hormone Replacement Therapy Revenue by Company (2020-2025)
• 2.3 Key Companies Hormone Replacement Therapy Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Hormone Replacement Therapy Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Hormone Replacement Therapy
• 2.6 Hormone Replacement Therapy Market Competitive Analysis
  • 2.6.1 Hormone Replacement Therapy Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Hormone Replacement Therapy Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Replacement Therapy as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Estrogen Hormone
  • 3.1.2 Growth Hormone
  • 3.1.3 Thyroid Hormone
  • 3.1.4 Testosterone Hormone
• 3.2 Global Hormone Replacement Therapy Sales Value by Type
  • 3.2.1 Global Hormone Replacement Therapy Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Hormone Replacement Therapy Sales Value, by Type (2020-2031)
  • 3.2.3 Global Hormone Replacement Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Menopause
  • 4.1.2 Hypothyroidism
  • 4.1.3 Growth Hormone Deficiency
  • 4.1.4 Male Hypogonadism
  • 4.1.5 Other Diseases
• 4.2 Global Hormone Replacement Therapy Sales Value by Application
  • 4.2.1 Global Hormone Replacement Therapy Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Hormone Replacement Therapy Sales Value, by Application (2020-2031)
  • 4.2.3 Global Hormone Replacement Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Hormone Replacement Therapy Sales Value by Region
  • 5.1.1 Global Hormone Replacement Therapy Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Hormone Replacement Therapy Sales Value by Region (2020-2025)
  • 5.1.3 Global Hormone Replacement Therapy Sales Value by Region (2026-2031)
  • 5.1.4 Global Hormone Replacement Therapy Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Hormone Replacement Therapy Sales Value, 2020-2031
  • 5.2.2 North America Hormone Replacement Therapy Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Hormone Replacement Therapy Sales Value, 2020-2031
  • 5.3.2 Europe Hormone Replacement Therapy Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Hormone Replacement Therapy Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Hormone Replacement Therapy Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Hormone Replacement Therapy Sales Value, 2020-2031
  • 5.5.2 South America Hormone Replacement Therapy Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Hormone Replacement Therapy Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Hormone Replacement Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Hormone Replacement Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Hormone Replacement Therapy Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.3.2 United States Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.4.2 Europe Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.5.2 China Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.6.2 Japan Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.7.2 South Korea Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Hormone Replacement Therapy Sales Value, 2020-2031
  • 6.9.2 India Hormone Replacement Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Hormone Replacement Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Eli Lilly
  • 7.1.1 Eli Lilly Profile
  • 7.1.2 Eli Lilly Main Business
  • 7.1.3 Eli Lilly Hormone Replacement Therapy Products, Services and Solutions
  • 7.1.4 Eli Lilly Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Eli Lilly Recent Developments
• 7.2 Pfizer
  • 7.2.1 Pfizer Profile
  • 7.2.2 Pfizer Main Business
  • 7.2.3 Pfizer Hormone Replacement Therapy Products, Services and Solutions
  • 7.2.4 Pfizer Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Pfizer Recent Developments
• 7.3 AbbVie
  • 7.3.1 AbbVie Profile
  • 7.3.2 AbbVie Main Business
  • 7.3.3 AbbVie Hormone Replacement Therapy Products, Services and Solutions
  • 7.3.4 AbbVie Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.3.5 AbbVie Recent Developments
• 7.4 Novo Nordisk
  • 7.4.1 Novo Nordisk Profile
  • 7.4.2 Novo Nordisk Main Business
  • 7.4.3 Novo Nordisk Hormone Replacement Therapy Products, Services and Solutions
  • 7.4.4 Novo Nordisk Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Novo Nordisk Recent Developments
• 7.5 Merck KGaA
  • 7.5.1 Merck KGaA Profile
  • 7.5.2 Merck KGaA Main Business
  • 7.5.3 Merck KGaA Hormone Replacement Therapy Products, Services and Solutions
  • 7.5.4 Merck KGaA Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Merck KGaA Recent Developments
• 7.6 Viatris
  • 7.6.1 Viatris Profile
  • 7.6.2 Viatris Main Business
  • 7.6.3 Viatris Hormone Replacement Therapy Products, Services and Solutions
  • 7.6.4 Viatris Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Viatris Recent Developments
• 7.7 Bayer
  • 7.7.1 Bayer Profile
  • 7.7.2 Bayer Main Business
  • 7.7.3 Bayer Hormone Replacement Therapy Products, Services and Solutions
  • 7.7.4 Bayer Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Bayer Recent Developments
• 7.8 Teva
  • 7.8.1 Teva Profile
  • 7.8.2 Teva Main Business
  • 7.8.3 Teva Hormone Replacement Therapy Products, Services and Solutions
  • 7.8.4 Teva Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Teva Recent Developments
• 7.9 Sandoz
  • 7.9.1 Sandoz Profile
  • 7.9.2 Sandoz Main Business
  • 7.9.3 Sandoz Hormone Replacement Therapy Products, Services and Solutions
  • 7.9.4 Sandoz Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Sandoz Recent Developments
• 7.10 Abbott
  • 7.10.1 Abbott Profile
  • 7.10.2 Abbott Main Business
  • 7.10.3 Abbott Hormone Replacement Therapy Products, Services and Solutions
  • 7.10.4 Abbott Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Abbott Recent Developments
• 7.11 Roche
  • 7.11.1 Roche Profile
  • 7.11.2 Roche Main Business
  • 7.11.3 Roche Hormone Replacement Therapy Products, Services and Solutions
  • 7.11.4 Roche Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Roche Recent Developments
• 7.12 Endo International
  • 7.12.1 Endo International Profile
  • 7.12.2 Endo International Main Business
  • 7.12.3 Endo International Hormone Replacement Therapy Products, Services and Solutions
  • 7.12.4 Endo International Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Endo International Recent Developments
• 7.13 Ipsen
  • 7.13.1 Ipsen Profile
  • 7.13.2 Ipsen Main Business
  • 7.13.3 Ipsen Hormone Replacement Therapy Products, Services and Solutions
  • 7.13.4 Ipsen Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Ipsen Recent Developments
• 7.14 ANI Pharmaceuticals
  • 7.14.1 ANI Pharmaceuticals Profile
  • 7.14.2 ANI Pharmaceuticals Main Business
  • 7.14.3 ANI Pharmaceuticals Hormone Replacement Therapy Products, Services and Solutions
  • 7.14.4 ANI Pharmaceuticals Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.14.5 ANI Pharmaceuticals Recent Developments
• 7.15 TherapeuticsMD
  • 7.15.1 TherapeuticsMD Profile
  • 7.15.2 TherapeuticsMD Main Business
  • 7.15.3 TherapeuticsMD Hormone Replacement Therapy Products, Services and Solutions
  • 7.15.4 TherapeuticsMD Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.15.5 TherapeuticsMD Recent Developments
• 7.16 Changchun Jinsai
  • 7.16.1 Changchun Jinsai Profile
  • 7.16.2 Changchun Jinsai Main Business
  • 7.16.3 Changchun Jinsai Hormone Replacement Therapy Products, Services and Solutions
  • 7.16.4 Changchun Jinsai Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.16.5 Changchun Jinsai Recent Developments
• 7.17 Takeda Pharmaceutical
  • 7.17.1 Takeda Pharmaceutical Profile
  • 7.17.2 Takeda Pharmaceutical Main Business
  • 7.17.3 Takeda Pharmaceutical Hormone Replacement Therapy Products, Services and Solutions
  • 7.17.4 Takeda Pharmaceutical Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.17.5 Takeda Pharmaceutical Recent Developments
• 7.18 Ascendis Pharma
  • 7.18.1 Ascendis Pharma Profile
  • 7.18.2 Ascendis Pharma Main Business
  • 7.18.3 Ascendis Pharma Hormone Replacement Therapy Products, Services and Solutions
  • 7.18.4 Ascendis Pharma Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.18.5 Ascendis Pharma Recent Developments
• 7.19 Halozyme Therapeutics
  • 7.19.1 Halozyme Therapeutics Profile
  • 7.19.2 Halozyme Therapeutics Main Business
  • 7.19.3 Halozyme Therapeutics Hormone Replacement Therapy Products, Services and Solutions
  • 7.19.4 Halozyme Therapeutics Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.19.5 Halozyme Therapeutics Recent Developments
• 7.20 Livzon
  • 7.20.1 Livzon Profile
  • 7.20.2 Livzon Main Business
  • 7.20.3 Livzon Hormone Replacement Therapy Products, Services and Solutions
  • 7.20.4 Livzon Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.20.5 Livzon Recent Developments
• 7.21 Hunrun Zizhu Pharma
  • 7.21.1 Hunrun Zizhu Pharma Profile
  • 7.21.2 Hunrun Zizhu Pharma Main Business
  • 7.21.3 Hunrun Zizhu Pharma Hormone Replacement Therapy Products, Services and Solutions
  • 7.21.4 Hunrun Zizhu Pharma Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.21.5 Hunrun Zizhu Pharma Recent Developments
• 7.22 Hikma Pharmaceuticals
  • 7.22.1 Hikma Pharmaceuticals Profile
  • 7.22.2 Hikma Pharmaceuticals Main Business
  • 7.22.3 Hikma Pharmaceuticals Hormone Replacement Therapy Products, Services and Solutions
  • 7.22.4 Hikma Pharmaceuticals Hormone Replacement Therapy Revenue (US$ Million) & (2020-2025)
  • 7.22.5 Hikma Pharmaceuticals Recent Developments

8 Industry Chain Analysis

• 8.1 Hormone Replacement Therapy Industrial Chain
• 8.2 Hormone Replacement Therapy Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Hormone Replacement Therapy Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Hormone Replacement Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer